• Akira Tsuburaya, Junichi Sakamoto, Satoshi Morita, Yasuhiro Kodera, Michiya Kobayashi, Yumi Miyashita, and John S Macdonald.
• Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahi-ku, Yokohama 2410815, Japan. tuburayaa@kcch.jp
• Jpn. J. Clin. Oncol. 2005 Nov 1; 35 (11): 672-5.

AbstractPaclitaxel, S1 and their combined sequential administration is proposed to be examined installing UFT as an active control of adjuvant chemotherapy for curatively resected T3-4 gastric cancer in a multicenter Phase III trial. The primary endpoint is disease-free survival and the secondary endpoints are incidence of adverse events, overall survival and compliance. The sample size is 370 per treatment arm (1480 in total) for two hypotheses of the superiority of sequential use of paclitaxel followed by oral fluoropyrimidines to fluoropyrimidines (UFT/S1) alone and the non-inferiority of S1 to UFT to be tested by two-by-two factorial design. Abdominal CT or US is performed every 3 months in the first 2 years and every 6 months thereafter for 3 years in total to ensure recurrence data collection. This trial could appraise sequential combination therapy and efficacy of new drugs as adjuvant for gastric cancer treatment.

29 keywords...

hide…